Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria
The study used a well-established animal model of proteinuria to determine the effect of MASP-2 inhibition on renal injury and fibrotic changes characteristic of proteinuric kidney diseases, including immunoglobulin A (IgA) nephropathy and lupus nephritis, which can often lead to end-stage kidney disease and dialysis. Both MASP-2-deficient and MASP-2 inhibitor-treated animals demonstrated marked renoprotection and reduction in inflammation from proteinuria with significantly less tubulointerstitial injury when compared to isotype antibody‑treated controls. Collectively, these findings indicate that MASP-2 inhibition may be broadly protective in proteinuric nephropathies.
Omeros’ lead MASP-2 inhibitor narsoplimab is in Phase 3 clinical programs for the treatment of IgA nephropathy and of atypical hemolytic uremic syndrome. In addition,
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely”, “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “prospects,” “should,” “slated,” “targeting,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements, including statements regarding Omeros’ research and development programs and the therapeutic application of Omeros’ research findings, are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, uncertainties inherent in research and development such as the risk that results of future clinical or preclinical studies may be different from those suggested by earlier results, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K filed with the
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations